BAM
ABUS icon

Bosun Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Bosun Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,932
Closed -$158K – 190
2024
Q3 		$158K Buy
+40,932
New +$157K 0.08% 179

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bosun Asset Management's ABUS Position: Q4 2024 in Review

Bosun Asset Management sold out of Arbutus Biopharma (ABUS) in Q4 2024, closing a stake of 40,932 shares — an estimated $158K sold.

Bosun Asset Management first reported a position in ABUS in Q3 2024 and held it in 1 quarter. The position peaked at $158K in Q3 2024. 153 funds tracked by Wall St. Rank hold ABUS as of Q4 2024.

  • Bosun Asset Management reported no remaining Arbutus Biopharma position as of Q4 2024 after selling out during the quarter.
  • Bosun Asset Management sold 40,932 Arbutus Biopharma shares in Q4 2024, an estimated $158K.
  • Bosun Asset Management first reported a position in Arbutus Biopharma in Q3 2024 and held it in 1 quarter.
  • Bosun Asset Management's Arbutus Biopharma position peaked at $158K in Q3 2024.
  • 153 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2024.

Based on Bosun Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.